HomeWhat is GSHArticlesFAQsGSH & DiseasesContact Us

 

 

 

 

home > articles > parkinson's disease

Glutathione Articles - Parkinson's Disease

  1. Sechi G; Deledda MG; Bua G; Satta WM; Deiana GA; Pes GM; Rosati G, Reduced intravenous glutathione in the treatment of early Parkinson’s disease. Prog Neurophyschopharmacol Biol Psychiatry, 20(7); 1159-70 1996 Oct.

  2. Johannsen P; Velander G; Mai J; Thorling EB; Dupont E, Glutathione peroxidase in early and advanced Parkinson’s disease. J Neurol Neurosurg Psychiatry, 54 (8); 679-82 1991 Aug.

  3. Spina MB; Cohen G, Dopamine turnover and glutathione oxidation: implications for Parkinson’s disease. Proc Natl Acad Sci U S A, 86(4); 1398-400 1989 Feb.

  4. Di Monte DA; Chan P; Sandy MS, Glutathione in Parkinson’s disease: A link between oxidative stress and mitochondrial damage? Ann Neurol. 1992 Suppl (32); S111-5.

  5. Sian J; Dexter DT; Lees AJ; Daniel S; Agid Y; Javoy-Agid F; Jenner P; Marsden CD, Alterations in glutathione levels in Parkinson’s disease and other neurodegenerative disorders affecting basal ganglia. Ann Neurol, 36(3); 348-55 1994 Sep.

  6. Merad-Boudia M; Santiard-Baron D; Saill’e C; Ceballos-Picot I, Mitochondrial impairment as an early event in the process of apoptosis induced by glutathione depletion in neuronal cells: Relevance to Parkinson’s disease. Biochem Pharmacol, 56(5):645-55 1998 Sep 1.

  7. Perry TL; Yong V, Idiopathic Parkinson's disease, progressive supranuclear palsy and glutathione metabolism in substantia nigra of patients. Neurosci Lett 1986; 67:269-74.

  8. Perry TL; Hansen S; Jones K, Brain amino acids and glutathione in progressive supranuclear palsy. Neurology 1988; 38:943-6.

  9. Riederer P; Sofic E; Rausch W; Schmidt B; Reynolds G; Jellinger K; Youdim M, Transition metals, ferrentin, glutathione, and ascorbic acid in pakinsonian brains. J Neurochem 1989; 52:515-520.

  10. Pearce R; Owen S; Daniel S; Jenner P; Marsden C, Alterations in the distribution of glutathione in substantia nigra in Parkinson's disease. J Neural Transm 1997; 104:661-77.

  11. Jenner P; Dexter D; Sian J; Schapira A; Marsden C; Oxidative stress as a cause of nigral cell death in Parkinson's disease and incidental lewy body disease. Ann Neurol 1992; 32:S82-S87.

  12. Perry TL; Godin D V; Hansen S; Jones K, Parkinson's Disease: a disorder due to nigral cell glutathione deficiency. Neurosci Lett 1982; 33:300-10.

  13. Jha N; Jurma O; Lalli G; Liu X; Pettus EH, et al, Glutathione Depletion in PC12 Results in Selective Inhibition of Mitochondrial Complex I Activity. J Biol Chem. 2000 Aug; Vol 275(34):26096-101.

  14. Sian J, Dexter DT, Lees AJ, Daniel S, Agid Y, Javoy-Agid F, Jenner P and Marsden CD. Alterations in glutathione levels in Parkinson's disease and other neurodegenerative disorders affecting basal ganglia. Ann Neurol. 1994 Sep;36(3):348-55.

  15. Chinta SJ, Kumar MJ, Hsu M, Rajagopalan S, Kaur D, Rane A, Nicholls DG, Choi J, and Andersen JK. Glutathione Depletion Leads to Symptoms of Parkinson's Disease in Mice. J Neurosci. 2007 Dec 19;27(51):13997-4006.

  16. Jenner P, Altered mitochondrial function, iron metabolism and glutathione levels in Parkinson's disease. Acta Neurol Scand Suppl. 1993;146:6-13.

  17. S. Canals, M. J. Casarejos, S. de Bernardo, E. RodrõÂguez-MartõÂn and M. A. Mena, Glutathione depletion switches nitric oxide neurotrophic effects to cell death in midbrain cultures: implications for Parkinson's disease. J Neurochem. (2001) 79, 1183-1195.

  18. Jenner P, What process causes nigral cell death in Parkinson's disease? Neurol Clin. 1992 May 10(2):387-403.

  19. Kidd P, Parkinson’s Disease as Multifactorial Oxidative Neurodegeneration: Implications for Integrative Management. Altern Med Rev 2000;5(6):502-545.

  20. Chinta SJ, Kumar MJ, Hsu M, Rajagopalan S, Kaur D, Rane A, Nicholls DG, Choi J, Andersen JK, Inducible Alterations of Glutathione Levels in Adult Dopaminergic Midbrain Neurons Result in Nigrostriatal Degeneration. Journal of Neuroscience, December 19,2007. 27(51):13997–14006.

  21. Hauser RA, Lyons KE, McClain T, Carter S, Perlmutter D, Randomized, double-blind, pilot evaluation of intravenous glutathione in Parkinson's disease. Mov Disord. 2009 Feb 19. [Epub ahead of print].

Video Testimony of Glutathione Use with Parkinson's Patients

Watch a video produced by Dr. David Perlmutter showing the before and after effects of IV glutathione on Parkinson's patients. > See Benefits of Glutathione


If you would like us to send you abstracts of any of the articles listed above (or full text PDF's when available), please contact us by phone or e-mail:

Caron Lassiter

Toll Free:
Tel: 800-227-2627
Fax: 800-369-0302
Local:
Tel: 205-879-6551
Fax: 205-871-2568
Email:
classiter@wellnesshealth.com

 

     
 


Glutathione Experts | What is Glutathione (GSH)? | Glutathione Articles | GSH FAQs | GSH & Diseases | Contact